<DOC>
	<DOCNO>NCT01372280</DOCNO>
	<brief_summary>Galantamine Hydrobromide Tablets , Bioequivalence study Dr. Reddy 's Fasting condition .</brief_summary>
	<brief_title>Galantamine Bioequivalence Study Dr. Reddy 's Under Fasting Condition</brief_title>
	<detailed_description>Comparative , Randomized , Single-Dose . 2-way Crossover Bioavailability Study Dr.Reddy 's laboratory , ltd. Janssen Pharmaceutical Products . L.P. ( ReminyteÂ® ) 4 mg Galantamine HBr Tablets In Healthy Adult Male Volunteers fast Conditions</detailed_description>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Subject candidate must fulfill follow inclusion criterion eligible participation study , unless otherwise specify : Healthy adult male volunteer , 1855 year age ; Weighing least 60 kg within 15 % ideal weight ( Table `` Desirable Weights Adults '' , Metropolitan Life Insurance Company , 1983 ) ; Medically healthy subject clinically normal laboratory profile . vital sign ECGs ; Give voluntary write informed consent participate study . Subject candidate must enrol study meet follow criterion : History presence significant cardiovascular , pUlmonary , hepatic , renal , hematologic . gastrointestinal , endocrine , immunologic . dermatologic , neurologic , psychiatric disease . In addition , history presence : alcoholism drug abuse within past year ; hypersensitivity idiosyncratic reaction galantamine anticholinesterase inhibitor ; asthma seizure . Subjects test positive screening HIV , HbsAg HeV . Subjects whose PR interval &gt; 200 msec screen prior dosing . Subjects whose QTc interval &gt; 450 msec screen prior dosing . Subjects use drug substance know strong inhibitor CYP enzyme ( formerly know cytochrome P450 enzyme ) within 28 day prior first dose . Subjects use drug substance know strong inducer CYP enzyme ( formerly know cytochrome P450 enzyme ) within 28 day prior first dose . Subjects special diet ( whatever reason ) 28 day prior first dose throughout study . Subjects , completion study , would donate excess : 500 mL blood 14 day ; 1500 mL blood 180 day ; 2500 ml blood 1 year . Subjects participate another clinical trial within 28 day prior first dose .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>